• 1
    Truelove S, Witts L. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955; ii: 10418.
  • 2
    Faubion W, Loftus E, Harmsen W, Zinsmeister A, Sandborn W. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 25560.
  • 3
    Hyde G, Thillainayagam A, Jewell D. Intravenous cyclosporine as rescue therapy in severe ulcerative colitis: time for a re-appraisal? Eur J Gastroenterol Hepatol 1998; 10: 4113.
  • 4
    Plevy S, Salzberg S, Regueiro M. A humanised anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid refractory UC: preliminary results of a phase 1 study. Gastroenterology 2003; 124: A7.
  • 5
    Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16: 699705.
  • 6
    Madsen SM, Schlichting P, Davidsen B, et al. An open-labeled, randomized study comparing systemic interferon-[alpha]-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001; 96: 180715.
  • 7
    Tilg H, Vogelsang H, Ludwiczek O, et al. A randomised placebo controlled trial of pegylated interferon-alpha in active ulcerative colitis. Gut 2003; 52: 172833.
  • 8
    Schreiber S, Fedorak R, Wild GE. Safety and tolerance of rhIL-10 treatment in patients with mild/moderate active ulcerative colitis. Gastroenterology 1998; 114: A10801.
  • 9
    Probert CSJ, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 9981002.
  • 10
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 72: 838.
  • 11
    Sandborn WJ, Rachmilewitz D, Hanauer S, et al. Infliximab induction and maintenance therapy for ulcerative colitis. DDW 2005 (Abstract ID 688).
  • 12
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1085811.
  • 13
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 246276.
  • 14
    Rutgeerts P, Feagan BG, Olson A, et al. A randomised placebo controlled trial of infliximab therapy for active ulcerative colitis: ACT 1 Trial. DDW 2005 (Abstract ID 689).
  • 15
    Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993; 151: 34606.
  • 16
    Goleva E, Kisich KO, Leung DYM. A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance. J Immunol 2002; 169: 593440.
  • 17
    Norman M, Hearing SD. Glucocorticoid resistance – what is known? Curr Opin Pharmacol 2002; 2: 7239.
  • 18
    Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326: 789.
  • 19
    Creed TJ, Norman MR, Probert CSJ, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 6575.
  • 20
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 3602.
  • 21
    Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 303: 106770.
  • 22
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 16259.
  • 23
    Baron J, Connell A, Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964; 1: 8992.
  • 24
    Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 90510.
  • 25
    Onrust S, Wiseman L. Basiliximab. Drugs 1999; 57: 20713.
  • 26
    Irvine E. A quality of life index for inflammatory bowel disease. Can J Gastroenterol 1993; 7: 1559.
  • 27
    Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 1748.
  • 28
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 18415.
  • 29
    Van Gossum A, Schmidt A, Adler M, et al. Short and long term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Acta Gastroenterol Belg 1997; 60: 197200.
  • 30
    Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 158792.
    Direct Link:
  • 31
    D'Haens G, Lemmens L, Vandeputte L, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 13239.
  • 32
    Van Assche G, D'haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis(1). Gastroenterology 2003; 125: 102531.
  • 33
    Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 2000; 12: 65760.
  • 34
    Boggi U, Danesi R, Vistoli F, et al. A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf 2004; 27: 91106.
  • 35
    Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98: 36976.